Singapore markets close in 7 hours 35 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
69.00-1.88 (-2.65%)
At close: 4:00PM EDT

69.19 +0.19 (0.28%)
After hours: 7:59PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close70.88
Open70.64
Bid69.09 x 1200
Ask69.19 x 1800
Day's range68.98 - 70.81
52-week range60.89 - 85.97
Volume12,281,881
Avg. volume10,061,401
Market cap86.552B
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)-0.20
Earnings date22 Oct 2020 - 26 Oct 2020
Forward dividend & yield2.72 (3.79%)
Ex-dividend date14 Sep 2020
1y target est80.17
  • State attorneys general urge U.S. to let other firms make Gilead COVID-19 drug
    Reuters

    State attorneys general urge U.S. to let other firms make Gilead COVID-19 drug

    The coalition of more than 30 state attorneys general called on the government to act or allow states to do so, saying in a letter to U.S. health agencies that Gilead "has not established a reasonable price" for remdesivir. "Gilead should not profit from the pandemic and it should be pushed to do more to help more people," the letter said.

  • Is Gilead Sciences a Buy After Its Disappointing Q2 Results?
    Motley Fool

    Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

    Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. Last week, Gilead announced second-quarter results that were below analysts' expectations. Gilead has been in the news quite a bit in recent months thanks to the clinical success for its COVID-19 therapy remdesivir.

  • Better Buy: Gilead Sciences vs. Pfizer
    Motley Fool

    Better Buy: Gilead Sciences vs. Pfizer

    Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE) are two of the most competent pharmaceutical companies in the industry. Recently, Gilead has been in the headlines thanks to its much-discussed antiviral drug remdesivir, which appears to be somewhat beneficial for treating coronavirus infections in certain patient populations. It helps that Gilead was an attractive company well before the pandemic, with normalized trailing 12-month diluted earnings per share (EPS) of $3.90 in contrast with Pfizer's $1.98 and a robust profit margin of 21.8%, slightly trailing Pfizer's 28.8%.